Claims for Patent: 9,845,354

Summary for Patent: 9,845,354

Title:	Anti-EPHRINB2 antibodies and methods using same
Abstract:	The invention provides anti-EphrinB2 antibodies, and compositions comprising and methods of using these antibodies.
Inventor(s):	Wu; Yan (Foster City, CA), Yan; Minhong (Foster City, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	15/053,964
Patent Claims:	1. A method of inhibiting angiogenesis comprising administration of an anti-EphrinB2 antibody to a subject in need of such treatment, wherein the anti-EphrinB2 antibody comprises (a) a light chain, wherein the light chain comprises three hypervariable regions (HVRs) and wherein SEQ ID NO:6 or 7 correspond to an HVR-L1, SEQ ID NO:8 or 9 correspond to an HVR-L2, SEQ ID NO:10, 11 or 12 correspond to an HVR-L3; and (b) a heavy chain, wherein the heavy chain comprises three HVRs and wherein SEQ ID NO:1 or 2 correspond to an HVR-H1, SEQ ID NO:3 or 4 correspond to an HVR-H2, and SEQ ID NO:5 corresponds to an HVR-H3. 2. The method of claim 1, further comprising administering to the subject an effective amount of an anti-angiogenic agent. 3. The method of claim 2, wherein the anti-angiogenic agent is administered prior to or subsequent to the administration of the anti-EphrinB2 antibody. 4. The method of claim 2, wherein the anti-angiogenic agent is administered concurrently with the anti-EphrinB2 antibody. 5. The method of claim 2, wherein the anti-angiogenic agent is an antagonist of vascular endothelial cell growth factor (VEGF). 6. The method of claim 5, wherein the VEGF antagonist is an anti-VEGF antibody. 7. The method of claim 6, wherein the anti-VEGF antibody is bevacizumab. 8. The method of claim 2, further comprising administering an effective amount of a chemotherapeutic agent. 9. The method of claim 1, further comprising administering an effective amount of a chemotherapeutic agent. 10. The method of claim 1, wherein the anti-EphrinB2 antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:6, 8, 10, 1, 3, 5. 11. The method of claim 1, wherein the anti-EphrinB2 antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 9, 11, 1, 3, 5. 12. The method of claim 1, wherein the anti-EphrinB2 antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:6, 8, 12, 2, 4, 5. 13. The method of claim 1, wherein at least a portion of the framework sequence of the anti-EphrinB2 antibody is a human consensus framework sequence. 14. The method of claim 13, wherein the anti-EphrinB2 antibody comprises human .kappa. subgroup consensus framework sequence. 15. The method of claim 13, wherein the anti-EphrinB2 antibody comprises heavy chain human subgroup III consensus framework sequence. 16. The method of claim 15, wherein the anti-EphrinB2 antibody comprises a substitution at one or more of position 71, 73 or 78. 17. The method of claim 16, wherein the substitution is one or more of R71A, N73T, or N78A.

Details for Patent 9,845,354

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2026-01-20